SETD2 and mantle cell lymphoma: We have previously reported that bortezomib is strikingly effective in reducing colony growth and inducing apoptosis both in SETD2/H3K36Me3-deficient HMC-1.1 and -1.2 cells and in neoplastic MCs from SETD2/H3K36Me3-deficient MCL patients [14].